1. Nejat A, Mirbolouk M, Mohebi R, Hasheminia M, Tohidi M, Saadat N, et al. Changes in lipid measures and incident coronary heart disease: Tehran Lipid & Glucose Study. Clin biochem. 2014;47(13-14):1239-44. [
DOI:10.1016/j.clinbiochem.2014.03.004] [
PMID]
2. Emerging Risk Factors Collaboration; N Sarwar, P Gao, S R Kondapally Seshasai, R Gobin, et al. Diabetes mellitus, fasting blood glucose concentration, and risk of vascular disease: a collaborative meta-analysis of 102 prospective studies. Lancet. 2010;375(9733):2215-22. [
DOI:10.1016/S0140-6736(10)60484-9]
3. Mongraw-Chaffin M, LaCroix AZ, Sears DD, Garcia L, Phillips LS, Salmoirago-Blotcher E, et al. A prospective study of low fasting glucose with cardiovascular disease events and all-cause mortality: The Women's Health Initiative. Metabolism. 2017;70:116-124. [
DOI:10.1016/j.metabol.2017.02.010] [
PMID] [
PMCID]
4. Kim H-K, Kim C-H, Kim EH, Bae SJ, Choe J, Park J-Y, et al. Impaired fasting glucose and risk of cardiovascular disease in Korean men and women: the Korean Heart Study. Diabetes Care. 2013;36(2):328-35. [
DOI:10.2337/dc12-0587] [
PMID] [
PMCID]
5. Esteghamati A, Zandieh A, Hafezi-Nejad N, Sheikhbahaei S, Abbasi M, Gouya MM, et al. Revising the fasting glucose threshold for detection of cardiovascular risk factors: analysing two representative population-based studies of more than 50 000 Iranians in 3 years: The National Survey of Risk Factors for Non-Communicable Diseases of Iran. Ann hum biol. 2015;42(2):150-8. [
DOI:10.3109/03014460.2014.932011] [
PMID]
6. Ghayour-Mobarhan M, Moohebati M, Esmaily H, Ebrahimi M, Parizadeh SMR, Heidari-Bakavoli AR, et al. Mashhad stroke and heart atherosclerotic disorder (MASHAD) study: design, baseline characteristics and 10-year cardiovascular risk estimation. Int J Public Health. 2015;60(5):561-72. [
DOI:10.1007/s00038-015-0679-6] [
PMID]
7. Perkins NJ, Schisterman EF. The Inconsistency of ''Optimal''Cutpoints Obtained using Two Criteria based on the Receiver Operating Characteristic Curve. Am J Epidemiol. 2006;163(7):670-5. [
DOI:10.1093/aje/kwj063] [
PMID] [
PMCID]
8. Aschner P. New IDF clinical practice recommendations for managing type 2 diabetes in primary care. Diabetes Res Clin Pract. 2017;132:169-170. [
DOI:10.1016/j.diabres.2017.09.002] [
PMID]
9. Shaye K, Amir T, Shlomo S, Yechezkel S. Fasting glucose levels within the high normal range predict cardiovascular outcome. Am Heart J. 2012;164(1):111-116. [
DOI:10.1016/j.ahj.2012.03.023] [
PMID] [
PMCID]
10. Pyorala K, Pedersen TR, Kjekshus J, Faergeman O, Olsson AG, Thorgeirsson G. Cholesterol lowering with simvastatin improves prognosis of diabetic patients with coronary heart disease: a subgroup analysis of the Scandinavian Simvastatin Survival Study (4S). Diabetes care. 1997;20(4):614-20. [
DOI:10.2337/diacare.20.4.614] [
PMID]
11. Briel M, Ferreira-Gonzalez I, You JJ, Karanicolas PJ, Akl EA, Wu P, et al. Association between change in high density lipoprotein cholesterol and cardiovascular disease morbidity and mortality: systematic review and meta-regression analysis. Bmj. 2009;338:b92. [
DOI:10.1136/bmj.b92] [
PMID] [
PMCID]
12. Idiopathic B, Endocrinopathies D. Report of the expert committee on the diagnosis and classification of diabetes mellitus. Diabetes care. 2003;26 suppl 1:S5-20. [
DOI:10.2337/diacare.26.2007.S5] [
PMID]
13. Huang C.L, Chang H.W, Chang J.B, Chen J.H, Lin J.D, Wu C.Z, et al. Normal fasting plasma glucose predicts type 2 diabetes and cardiovascular disease in elderly population in Taiwan. QJM. 2016;109(8):515-22. [
DOI:10.1093/qjmed/hcv204] [
PMID] [
PMCID]
14. Bao C, Zhang D, Sun B, Lan L, Cui W, Xu G, et al. Optimal cut-off points of fasting plasma glucose for two-step strategy in estimating prevalence and screening undiagnosed diabetes and pre-diabetes in Harbin, China. PloS one. 2015;10(3):e0119510. [
DOI:10.1371/journal.pone.0119510] [
PMID] [
PMCID]